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lectures by Eli Lilly1998, a clinical classiﬁcation of pulmonary hypertension (PH) was established, categorizing PH into groups which
share similar pathological and hemodynamic characteristics and therapeutic approaches. During the 5th World
Symposium held in Nice, France, in 2013, the consensus was reached to maintain the general scheme of previous
clinical classiﬁcations. However, modiﬁcations and updates especially for Group 1 patients (pulmonary arterial
hypertension [PAH]) were proposed. The main change was to withdraw persistent pulmonary hypertension of the
newborn (PPHN) from Group 1 because this entity carries more differences than similarities with other PAH
subgroups. In the current classiﬁcation, PPHN is now designated number 1. Pulmonary hypertension associated with
chronic hemolytic anemia has been moved from Group 1 PAH to Group 5, unclear/multifactorial mechanism. In
addition, it was decided to add speciﬁc items related to pediatric pulmonary hypertension in order to create
a comprehensive, common classiﬁcation for both adults and children. Therefore, congenital or acquired left-heart
inﬂow/outﬂow obstructive lesions and congenital cardiomyopathies have been added to Group 2, and segmental
pulmonary hypertension has been added to Group 5. Last, there were no changes for Groups 2, 3, and 4.
(J Am Coll Cardiol 2013;62:D34–41) ª 2013 by the American College of Cardiology FoundationPulmonary hypertension (PH) was previously classiﬁed into
2 categories: 1) primary pulmonary hypertension; or 2)
secondary pulmonary hypertension according to the presence
of identiﬁed causes or risk factors (1).
Since the second World Symposium on pulmonary
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D35pulmonary hypertension due to chronic lung disease and/or
hypoxia (Group 3); chronic thromboembolic pulmonary
hypertension (Group 4); and pulmonary hypertension due to
unclear multifactorial mechanisms (Group 5). During the
successive world meetings, a series of changes were carried
out, reﬂecting some progresses in the understanding of the
disease. However, the general architecture and the philosophy
of the clinical classiﬁcation were unchanged. The current
clinical classiﬁcation of pulmonary hypertension (3) is now
well accepted and, widely used in the daily practice of
pulmonary hypertension experts. It has been adopted by the
Guidelines Committee of the Societies of Cardiology and,
Pneumology (4,5). Moreover, this classiﬁcation is currently
used by the U.S. Food and Drug Administration and the
European Agency for Drug Evaluation for the labelling of
new drugs approved for pulmonary hypertension.
During the Fifth World Symposium held in 2013 in
Nice, France, the consensus was to maintain the general
disposition of previous clinical classiﬁcation. Some
modiﬁcations and updates, especially for Group 1, were
proposed according to new data published in the last
years. It was also decided in agreement with the Task
Force on Pediatric PH to add some speciﬁc items related
to pediatric pulmonary hypertension in order to have
a comprehensive classiﬁcation common for adults and
children (Table 1).
Group 1: Pulmonary Arterial Hypertension (PAH)
Since the second World Symposium in 1998, the nomen-
clature of the different subcategories of Group 1 have
markedly evolved and, additional modiﬁcation were made in
the Nice classiﬁcation.
Heritable Pulmonary Hypertension
In 80% of families with multiple cases of pulmonary arterial
hypertension (PAH), mutations of the bone morphogenic
protein receptor type 2 (BMPR2), a member of the tumor
growth factor (TGF)-beta super family, can be identiﬁed
(6). In addition, 5% of patients have rare mutations in other
genes belonging to the TGFb super family: activin-like
receptor kinase-1 (ALK1) (7), endoglin (ENG) (8),
and mothers against decapentaplegic 9 (Smad 9) (9).
Approximately 20% of families have no detectable mutations
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identiﬁed: a mutation in cav-
eolin-1 (CAV1) which encodes
a membrane protein of caveolae,
abundant in the endothelial cells
of the lung (10), and KCNK3, a
gene encoding potassium channel
super family K member-3 (11).
The identiﬁcation of these new
genes not intimately related to
TGFb signaling may provide new




A number of drugs and toxins
have been identiﬁed as risk fac-
tors for the development of PAH
and were included in the previous
classiﬁcation (3). Risk factors
were categorized according to
the strength of evidence, as deﬁ-
nite, likely, possible, or unlikely
(Table 2).
A deﬁnite association is de-
ﬁned as an epidemic or large
multicenter epidemiologic studies
demonstrating an association between a drug and PAH. A
likely association is deﬁned as a single case-control study
demonstrating an association or a multiple-case series.
Possible is deﬁned as drugs with similar mechanisms of action
as those in the deﬁnite or likely category but which have not
yet been studied. Last, an unlikely association is deﬁned as
one in which a drug has been studied in epidemiologic studies
and an association with PAH has not been demonstrated.
Over the last 5 years, new drugs have been identiﬁed or
suspected as potential risk factors for PAH.
Since 1976, Benﬂuorex (MEDIATOR, Laboratories
Servier, Neuilly-Sur-Seine, France) has been approved in
Europe as a hypolipidemic and hypoglycemic drug. This
drug is in fact a fenﬂuramine derivative, and its main
metabolite is norfenﬂuramine, similar to Isomeride. Ben-
ﬂuorex, due to its pharmacological properties, was with-
drawn from the market in all European countries after 1998
(date of the worldwide withdrawal of fenﬂuramine deriva-
tives), except in France where the drug was marketed until
2009 and was frequently used between 1998 and 2009 as
a replacement for Isomeride. The ﬁrst case series reporting
benﬂuorex-associated PAH was published in 2009. In
addition to 5 cases of severe PAH, 1 case of valvular disease
was also reported (12). Recently, Savale et al. (13) reported
85 cases of PAH associated with benﬂuorex exposure,
identiﬁed in the French national registry from 1999 to 2011.
Of these cases, 70 patients had conﬁrmed pre-capillary
Table 2





Dexfenﬂuramine St. John’s wort
Toxic rapeseed oil Chemotherapeutic agents







*Nice 2013. ySelective serotonin reuptake inhibitor (SSRIs) have been demonstrated as a risk
factor for the development of persistent pulmonary hypertension in the newborn (PPHN) in preg-
nant women exposed to SSRIs (especially after 20 weeks of gestation). PPHN does not strictly
belong to Group 1 (pulmonary arterial hypertension [PAH]) but to a separated Group 1. Main
modiﬁcation to the previous Danapoint classiﬁcation are in bold.
Table 1 Updated Classiﬁcation of Pulmonary Hypertension*




1.2.2 ALK-1, ENG, SMAD9, CAV1, KCNK3
1.2.3 Unknown
1.3 Drug and toxin induced
1.4 Associated with:
1.4.1 Connective tissue disease
1.4.2 HIV infection
1.4.3 Portal hypertension
1.4.4 Congenital heart diseases
1.4.5 Schistosomiasis
10 Pulmonary veno-occlusive disease and/or pulmonary capillary hemangiomatosis
10 0. Persistent pulmonary hypertension of the newborn (PPHN)
2. Pulmonary hypertension due to left heart disease
2.1 Left ventricular systolic dysfunction
2.2 Left ventricular diastolic dysfunction
2.3 Valvular disease
2.4 Congenital/acquired left heart inﬂow/outﬂow tract obstruction and
congenital cardiomyopathies
3. Pulmonary hypertension due to lung diseases and/or hypoxia
3.1 Chronic obstructive pulmonary disease
3.2 Interstitial lung disease
3.3 Other pulmonary diseases with mixed restrictive and obstructive pattern
3.4 Sleep-disordered breathing
3.5 Alveolar hypoventilation disorders
3.6 Chronic exposure to high altitude
3.7 Developmental lung diseases
4. Chronic thromboembolic pulmonary hypertension (CTEPH)
5. Pulmonary hypertension with unclear multifactorial mechanisms
5.1 Hematologic disorders: chronic hemolytic anemia, myeloproliferative
disorders, splenectomy
5.2 Systemic disorders: sarcoidosis, pulmonary histiocytosis,
lymphangioleiomyomatosis
5.3Metabolicdisorders: glycogenstoragedisease,Gaucherdisease, thyroiddisorders
5.4 Others: tumoral obstruction, ﬁbrosing mediastinitis, chronic renal failure,
segmental PH
*5th WSPH Nice 2013. Main modiﬁcations to the previous Dana Point classiﬁcation are in bold.
BMPR ¼ bone morphogenic protein receptor type II; CAV1 ¼ caveolin-1; ENG ¼ endoglin;
HIV ¼ human immunodeﬁciency virus; PAH ¼ pulmonary arterial hypertension.
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D36pulmonary hypertension (PH) with a median ingestion
duration of 30 months and a median delay between start of
exposure and diagnosis of 108 months. One-quarter of
patients in these series showed coexisting PH and mild to
moderate valvular heart diseases (14).
Chronicmyeloproliferative (CML)disorders are a rare cause
of PH, involving various potential mechanisms (Group 5)
including high cardiac output, splenectomy, direct obstruc-
tion of pulmonary arteries, chronic thromboembolism,
portal hypertension, and congestive heart failure. The
prognosis of CML has been transformed by tyrosine kinase
inhibitors (TKIs) such as imatinib, dasatinib, and nilotinib.
Although, TKIs are usually well tolerated, these agents are
associated nevertheless with certain systemic side effects
(edema, musculoskeletal pain, diarrhea, rash, pancytopenia,
elevation of liver enzymes). It is also well established
that imatinib may induce cardiac toxicity. Pulmonary
complications and speciﬁcally pleural effusions have been
reported more frequently with dasatinib. In addition, case
reports suggested that PHmay be a potential complication of
dasatinib use (15).Montani et al. (16) recently published incidental cases of
dasatinib-associated PAH reported in the French registry.
Between November 2006 and September 2010, 9 cases
treated with dasatinib at the time of PH diagnosis were
identiﬁed. At diagnosis, patients had moderate to severe pre-
capillary PH conﬁrmed by heart right catheterization. No
other PH cases were reported with other TKIs at the time
of PH diagnosis. Interestingly, clinical, functional, and
hemodynamic improvements were observed within 4 months
of dasatinib discontinuation in all but 1 patient. However,
after a median follow-up of 9 months, most patients did not
demonstrate complete recovery, and 2 patients died. Today,
more than 13 cases have been observed in France among
2,900 patients treated with dasatinib for CML during the
same period, giving the lowest estimate incidence of
dasatinib-associated PAH of 0.45%. Finally, notiﬁcations of
almost 100 cases of PH have been submitted for European
pharmaceutical vigilance. Dasatinib is considered a likely risk
factor for PH (Table 2).
Few cases of PAH associated with the use of interferon
(IFN)-a or -b (17,18) have been published so far. Recently,
all cases of PAH patients with a history of IFN therapy
notiﬁed in the French PH registry were analyzed (19). Fifty-
three patients with PAH and a history of IFN use were
identiﬁed between 1998 and 2012. Forty-eight patients were
treated with IFN-a for chronic hepatitis C, most of them
had an associated risk factor for PH such as human
immunodeﬁciency virus (HIV) infection and/or portal
hypertension. Five other cases were treated with IFNb for
multiple sclerosis; those patients did not have any associated
risks factor for PAH. The mean delay between initiation of
IFN therapy and PAH diagnosis was approximately 3 years.
Sixteen additional patients with previously documented
PAH were treated with IFN-a for hepatitis C and showed
a signiﬁcant increase in pulmonary vascular resistance (PVR)
within a few months of therapy initiation; in half of them,
withdrawal of IFN resulted in a marked hemodynamic
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D37improvement. Regarding a potential mechanism, several
experimental studies have found that IFN-a and INF-b
induced the release of endothelin-1 by pulmonary vascular
cells (20).
In summary, this retrospective analysis of the French
registry together with experimental data suggested that IFN
therapy may be a trigger for PAH. However, most of the
patients exposed to IFN also had some other risk factors for
PAH, and a prospective case control study is mandatory to
deﬁnitively establish a link between IFN exposure and
development of PAH. At this time, IFN-a and -b are
considered possible risks factors of PH.
Persistent PH of the newborn (PPHN) is a life-
threatening condition that occurs in up to 2 per 1,000
live-born infants. During the past 15 years, many studies
have speciﬁcally assessed the associations between use of
serotonin reuptake inhibitors (SSRIs) during pregnancy and
the risk of PPHN with discordant results from no associa-
tion to 6-fold increased risk (21–26).
A recent study involving nearly 30,000 women who had
used SSRIs during pregnancy found that every use in late
pregnancy increased the risk of PPHN by more than
2-fold. Based on this large study, SSRIs can be considered
a deﬁnite risk factor for PPHN (27). Whether exposure to
SSRIs is associated with an increased risk of PAH in adults
is unclear.
Although presently there is no demonstrated association
with PAH, several drugs with mechanisms of actions similar
to amphetamines, used to treat a variety of conditions
including obesity (fentermine/topiramate [Qsiva]), attention
deﬁcit disorder (methylphenidate) (28), Parkinson’s disease
(ropinirole), and narcolepsy (mazindol), need to be moni-
tored closely for an increase in cases of PAH.
In summary, several new drugs have recently been iden-
tiﬁed as deﬁnite, likely, or possible risk factors for PAH. In
order to improve detection of potential drugs that induce
PAH, it is important to outline the critical importance of
obtaining a detailed history of current and prior exposure in
every PAH patient. The proliferation of national and
international registries should provide the unique opportu-
nity to collect these data prospectively. In addition, one must
emphasize the need to report all side effects of drugs to local
pharmaceutical agencies and pharmaceutical companies.
PAH Associated With Connective Tissue Diseases
The prevalence of PAH is well established only in sclero-
derma, and rate of occurrence is estimated between 7% and
12% (29,30). The prognosis for patients with PAH associ-
ated with scleroderma remains poor and worse compared to
other PAH subgroups. The 1-year mortality rate in patients
with idiopathic PAH is approximately 15% (31) versus 30%
in PAH-associated with scleroderma (32). Recent data
suggest that in scleroderma, early diagnosis and early
intervention may improve long-term outcome (33). Inter-
estingly, it has been recently demonstrated that sclerodermapatients with a mean pulmonary artery pressure (PAP)
between 21 and 24 mm Hg are at high risk for the devel-
opment of overt PH within 3 years and should be closely
followed (34).
PAH Associated With HIV Infection
The prevalence of PAH associated with HIV infection has
remained stable within the last decade, estimated to be 0.5%
(35). Before the era of highly active antiretroviral therapy
(HAART) and the development of speciﬁc PAH drugs, the
prognosis for HIV-PAH was extremely poor, with a
mortality rate of 50% in 1 year (36). The advent of HAART
and the wide use of PAH therapies in HIV patients have
dramatically improved their prognosis, and the current
survival rate at 5 years in the French cohort is more than
70% (37). Interestingly, approximately 20% of these cases
experience a normalization of hemodynamic parameters after
several years of treatment (38).
PAH Associated With Portal Hypertension
Hemodynamic studies have shown that PAH is conﬁrmed
in 2% to 6% of patients with portal hypertension, so called
portopulmonary hypertension (POPH) (39,40). The risk of
developing POPH is independent of the severity of the liver
disease (41). Long-term prognosis is related to the severity
of cirrhosis and to cardiac function (41). There is wide
discrepancy in the published survival estimates of patients
with POPH. In, the U.S. REVEAL registry (42) patients
with POPH had a poor prognosis, even worse that those
with idiopathic PAH with a 3-year survival rate of 40%
versus 64%, respectively. In the French registry, the 3-year
survival rate of POPH was 68%, slightly better than that
of idiopathic PAH (43). These discordant results are likely
explained by important differences with respect to the
severity of liver disease. In the U.S. REVEAL registry,
most of these patients were referred from liver trans-
plantation centers, whereas in the French cohort, most
patients had mild cirrhosis (39–43).
PAH Associated With
Congenital Heart Disease in Adults
Increasing numbers of children with congenital heart di-
sease (CHD) now survive to adulthood. This reﬂects im-
provement in CHD management in recent decades, and
both the number and complexity of adults with CHD
continue to increase. It is estimated that 10% of adults with
CHD may also have PAH (44). The presence of PAH in
CHD has an adverse impact on quality of life and outcome
(45,46).
A well-recognized clinical phenotype of patients with
volume and pressure overload (i.e., with large ventricular or
arterial shunts) are at much higher risk of developing early
PAH than patients with volume overload only (i.e., with
atrial shunts). Nevertheless, there are some exceptions, and
Table 4
Criteria for Closing Cardiac Shunts in PAH Patients
Associated With Congenital Heart Defects*
PVRi, Wood units/m2 PVR, Wood units Correctabley
<4 <2.3 Yes
>8 >4.6 No
4-8 2.3–4.6 Individual patient evaluation
in tertiary centers
*Criteria: the long-term impact of defect closure in the presence of pulmonary arterial hypertension
(PAH) with increased PVR is largely unknown. There are a lack of data in this controversial area,
and caution must be exercised. yCorrectable with surgery or intravascular nonsurgical procedure.
PVR ¼ pulmonary vascular resistance; PVRi ¼ pulmonary vascular resistance index.
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D38we speculate that a permissive genotype might place some
patients with CHD at higher risk of developing PAH.
Given the prevalence of PAH among adults with CHD, we
suggest that every patient with CHD merits an appropriate
assessment in a tertiary setting to determine whether PAH is
present. While it is anticipated that the number of patients
with Eisenmenger syndrome, the extreme end of the PAH/
CHD spectrum, complicated also by chronic cyanosis, will
decrease in the coming years and there will be an increasing
number of patients with complex and/or repaired CHD
surviving to adulthood with concomitant PH (47). The
present clinical subclassiﬁcation of PAH associated with
CHDs has evolved sensibly from 2008. It remains clinical
and simple, thus widely applicable. Importantly, it is now
aligned with the Nice Pediatric classiﬁcation, as PAH in
association with CHD is a lifelong disease (Table 3). We
have proposed criteria for shunt closure in patients with net
left to right shunting who may represent a management
dilemma (Table 4). Other types of PH in association with
CHD who do not belong to Group 1 (PAH) are included in
different groups of the general clinical classiﬁcation (i.e.,
congenital or acquired left heart inﬂow/outﬂow obstructive
lesions and congenital cardiomyopathies in Group 2).
Segmental PH (PH in one or more lobes of one or both
lungs) is included in Group 5. In addition, some patients
with PH associated with CHD are difﬁcult to classify, such
as patients with transposition of great arteries and those
with PH following atrial redirection surgery or following
neonatal arterial switch operation. This reinforces the need
to delineate the underlying cardiac anatomy/physiology and
severity of PAH/PVR in every single patient. Here we make
speciﬁc reference to patients with the Fontan circulation
(atrio- or cavopulmonary connections as palliation for “singleTable 3
Updated Clinical Classiﬁcation of Pulmonary Arterial
Hypertension Associated With Congenital Heart
Disease*
1. Eisenmenger syndrome
Includes all large intra- and extra-cardiac defects which begin as systemic-to-
pulmonary shunts and progress with time to severe elevation of pulmonary
vascular resistance (PVR) and to reversal (pulmonary-to-systemic) or
bidirectional shunting; cyanosis, secondary erythrocytosis and multiple organ




Include moderate to large defects; PVR is mildly to moderately increased
systemic-to-pulmonary shunting is still prevalent, whereas cyanosis is not
a feature.
3. Pulmonary arterial hypertension (PAH) with coincidental congenital heart disease
Marked elevation in PVR in the presence of small cardiac defects, which
themselves do not account for the development of elevated PVR; the clinical
picture is very similar to idiopathic PAH. To close the defects in contraindicated.
4. Post-operative PAH
Congenital heart disease is repaired but PAH either persists immediately after
surgery or recurs/develops months or years after surgery in the absence of
signiﬁcant postoperative hemodynamic lesions. The clinical phenotype is often
aggressive.
*Nice 2013.ventricle” type hearts), who do not fulﬁll standard criteria for
PH but may have an increased PVR. There are very limited
surgical alternatives for this group of patients with complex
anatomy/physiology. There has been some recent evidence
of potential clinical response to speciﬁc PAH therapies in
Fontan patients, which needs further exploration before
therapeutic recommendations can been made (48,49).
PAH Associated With Schistosomiasis
Schistosomiasis-associated PAH (Sch-PAH) was included
in Group 1 in 2008. Previously it was in Group 4 (chronic
thromboembolism disease). Today, Sch-PAH is potentially
the most prevalent cause of PAH worldwide. Schistosomi-
asis affects over 200 million people, of whom 10% develop
hepatosplenic schistomiasis (50). PAH occurs almost
exclusively in this population, and 5% of patients with
hepatosplenic schistosomiasis may develop PAH (51). The
hemodynamic proﬁle of Sch-PAH is similar to that of
POPH (52). Its mortality rate may reach up to 15% at 3
years (52). Recent uncontrolled data indicate that PAH
therapies may beneﬁt patients with Sch-PAH (53).
Chronic Hemolytic Anemia
Chronic hemolytic anemia such as sickle cell disease, thal-
assemia, spherocytosis, and stomatocytosis are associated
with an increased risk of PH. The cause of PH is unclear
and often multifactorial, including chronic thromboembo-
lism, splenectomy, high cardiac output, left-heart disease,
and hyperviscosity; the role of an inactivation of nitric oxide
by free plasma hemoglobin due to chronic hemolysis is
controversial (54,55).
The prevalence and characteristic of PH in chronic
hemolytic anemia has been extensively studied only in sickle
cell disease (SCD). In SCD, PH conﬁrmed by right-heart
catheterization and deﬁned as a mean PAP 25 mm Hg
occurs in 6.2% (56) to 10% of patient (57). Post-capillary
PH due to left-heart disease represents the most frequent
cause, with a prevalence of 3.3% (56) to 6.3% (57). The
prevalence of pre-capillary PH is lower but not rare: 2.9%
(56) to 3.7% (57). The classiﬁcation of pre-capillary PH
associated with SCD has evolved during the successive
world meetings, revealing uncertainties in potential causes.
Table 5
Hemodynamic Characteristics in Patients With
PH Associated With SCD in 3 Different Cohorts:











RAP, mm Hg 10  6 d 10  5
mPAP, mm Hg 30  6 33.1  8.9 36  9
PCWP, mm Hg 16  7 16.0  5.7 16  5
CO, l/min–CI, l/min/m2* 8.7  1.9 5.00  1.36* 8  3
PVR, dyn$s$cm5 138  58 179  120 229  149
*Cardiac index use instead of cardiac output in the Brazilian cohort.
CI ¼ cardiac index; CO ¼ cardiac output; mPAP ¼ mean pulmonary artery pressure;
PCWP ¼ pulmonary capillary wedge pressure; PH ¼ pulmonary hypertension; PVR ¼ pulmonary
vascular resistance; RAP ¼ right atrial pressure; SCD ¼ sickle cell disease.
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(chronic thromboembolism). In the Venice and Dana Point
classiﬁcations (3), it was shifted to Group 1 (PAH). Pre-
capillary PHs belonging to Group 1 share some character-
istics: 1) histological ﬁndings of major proliferation of the
wall of pulmonary arteries including plexiform lesions;
2) severe hemodynamic impairment, with PVR >3 Woods
units (240 dyn$s$cm5); and 3) well-documented response
to PAH-speciﬁc therapies.
In SCD, autopsy studies providing insight into the
characteristics of pulmonary vascular lesions are limited.
The best-documented study (58) reported 20 cases and
obtained photomicrographs of the lesions; among them,
12 patients were considered having plexiform lesions. In
fact, 8 of these 12 cases had histological evidence of hepatic
cirrhosis, which is a major confounding factor. Moreover,
the picture of the pulmonary vascular changes considered
plexiform lesions were not typical and may correspond to
recanalyzed thrombi (P. Dorfmüller, personal communica-
tion, February 2013). Another autopsy study of 21 cases
(59) reported 66.6% of microthrombotic and/or thrombo-
embolic lesions, whereas mild moderate or severe pulmonary
vasculopathy was observed in only one-third of this
population. A larger autopsy study of 306 cases of SCD
patients with a clinical suspicion of PH found thrombo-
embolic lesions in 24% but no cases of pulmonary vascul-
opathy lesions (60). A recent review of autopsy cases in








RAP, mm Hg 8  5 7  5 8 
mPAP, mm Hg 49  13 41  9 47 
PCWP, mm Hg 9  4 8  4 9 
Cardiac index, l/min/m2 2.4  0.8 2.8  0.9 3.0 
PVR, dyn$s$cm5 831  461 649  379 611 
Values are mean  SD.
CHD ¼ congenital heart disease; CTD ¼ connective tissue disorders; HIV ¼ human immunodeﬁciency v
PCWP ¼ pulmonary capillary wedge pressure; PH ¼ pulmonary hypertension; POPH ¼ portopulmonary
disease.vascular injuries are quite common in patients with SCD;
however, not a single case with plexiform lesions could be
found (61).
Three recent hemodynamic studies provided baseline
hemodynamic data in patients with SCD and PH (56–62).
Findings were similar among the 3 cohorts, with a high
cardiac output between 8 and 9 l/min and moderate eleva-
tion in mean PAP (from 30 to 60 mm Hg) (Table 5). SCD
patients with a pre-capillary PH had a modest elevation in
PVR that was 3 or 4 times less than PVR observed in other
PAH subgroups (Table 6). Among the 11 patients of the
French SCD cohort with a conﬁrmed pre-capillary PH
(mean pulmonary artery pressure [mPAP] 25 mm Hg and
pulmonary capillary wedge pressure 15 mm Hg), no
patient fulﬁlled the hemodynamic criteria for PAH, deﬁned
as PVR >250 dyn$s$cm5 (56).
Speciﬁc therapies approved for the treatment of PAH
include prostacyclin derivatives, endothelin receptor antago-
nists, and phosphodiesterase-5 inhibitors. However, none of
these agents is currently approved for the treatment of
PH associated with SCDdue to the lack of data in this speciﬁc
population. Recently, the effect of bosentan was assessed in
a randomized double-blind placebo-controlled trial of
patients with sickle cell disease and PH (63). Overall,
bosentan appeared to be well tolerated, although the small
sample size precluded an analysis of its efﬁcacy. Another
randomized, double-blind, placebo-controlled study designed
to evaluate the safety and efﬁcacy of sildenaﬁl was prematurely
halted after interim analysis showed that sildenaﬁl-treated
patients were likely to have more acute sickle cell pain crises
(35%) than placebo-treated patients (14%) (64). Furthermore,
there was no evidence of treatment-related improvement at
the time of study termination (64).
In summary, pre-capillary PH associated with SCD
appears signiﬁcantly different from other forms of PAH in
regard to pathological ﬁndings, hemodynamic characteris-
tics, and response to PAH-speciﬁc therapies. Therefore, it
was decided to move PH associated with SCD from Group 1
(PAH) to Group 5 (unclear multifactorial mechanisms).
Other PH Groups
Persistent PH of the newborn has been withdrawn from









6 7  5 8  5 5  2
12 51  16 49  10 28  4
04 8  4 9  5 10  3
1.0 3.0  1.0 2.9  0.7 5.8  1.3
311 753  370 737  328 178  55
irus; IPAH ¼ idiopathic pulmonary arterial hypertension; mPAP ¼ mean pulmonary artery pressure;
hypertension; PVR ¼ pulmonary vascular resistance; RAP ¼ right atrial pressure; SCD ¼ sickle cell
Simonneau et al. JACC Vol. 62, No. 25, Suppl D, 2013
Classification of Pulmonary Hypertension December 24, 2013:D34–41
D40differences than similarities with other PAH subgroups. In
the current classiﬁcation, PPHN is designated 1. In
agreement with the pediatric classiﬁcation (65), congenital
or acquired left-heart inﬂow/outﬂow obstructive lesions
and congenital cardiomyopathies have been added to
Group 2. There is no change for Group 3 (PH due to lung
diseases and/or hypoxia) and for Group 4 (chronic
thromboembolism). In Group 5 (unclear multifactorial
mechanisms) chronic hemolytic anemia and segmental PH
(pediatric classiﬁcation) have been included. An update for
Groups 2, 3, and 4 will be published separately in the same
issue of this supplement (66–68), providing some impor-
tant adaptations regarding deﬁnitions and management.
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